EGFR and lung adenocarcinoma: As shown in Figure 1, we found that patients in wild-type EGFR lung adenocarcinoma with higher FGFR4 expression had shorter overall survival times and five-years survival times compared with those with lower FGFR4 expression (p = 0.008; Figure 1A; p = 0.006; Figure 1B).